Human vaccines & immunotherapeutics: News May 2023

Ronald Ellis,Adam Weiss

DOI: https://doi.org/10.1080/21645515.2023.2223053

2023-06-30

Abstract:The US Food and Drug Administration (FDA) has approved two vaccines for prevention of respiratory syncytial virus (RSV) infection in adults ≥60 years old. Both vaccines target the prefusion form of the viral F protein, which mediates cell entry.

immunology,biotechnology & applied microbiology

What problem does this paper attempt to address?

RSV immunization in adults and children: A practical guide for clinicians

Trate DeVolld,Kaitlyn R Rivard

DOI: https://doi.org/10.3949/ccjm.91.s1.03

2024-09-04

Abstract:In 2023 and 2024, 3 vaccines were approved by the US Food and Drug Administration (FDA) against respiratory syncytial virus (RSV) in adults. In addition, the first long-acting RSV monoclonal antibody for infants and young children was approved. This review provides clinicians with practical guidance to navigate this new era of RSV prevention.
Respiratory Syncytial Virus Prevention: A New Era of Vaccines

Calvin Yee Fen Lee,Salman J Khan,Fnu Vishal,Sadaf Alam,Syeda Fatima Murtaza

DOI: https://doi.org/10.7759/cureus.45012

2023-09-11

Cureus

Abstract:Respiratory syncytial virus (RSV) is a pathogen that primarily affects the respiratory system, leading to upper and lower respiratory tract infections. Children, individuals aged 60 and above, and individuals with impaired immune systems are more susceptible to developing RSV lower respiratory tract infections (LRTIs), which can result in fatalities in some instances. Symptoms of LRTI include shortness of breath, wheezing, pneumonia, and bronchiolitis. Current management of RSV-LRTI includes conservative and symptomatic treatment. The Food and Drug Administration (FDA) recently approved two vaccines that effectively prevent acute and severe RSV-LRTI requiring hospitalizations. Nirsevimab (Beyfortus) is approved for infants born at 35 weeks of gestation and above. At the same time, RSVPreF3 OA (Arexvy) is recommended for adults aged 60 and older. Both vaccines are effective against the two major strains of RSV and require single doses to induce immunity. In this article, we will discuss the mechanism of action, effectiveness, and side effects of these novel vaccines and their possible impact.
Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants

Yahiya Y. Syed

DOI: https://doi.org/10.1007/s40272-023-00598-3

2023-10-14

Paediatric Drugs

Abstract:Pfizer is developing a bivalent respiratory syncytial virus (RSV) prefusion F subunit vaccine (RSVpreF; ABRYSVOTM) for preventing RSV illness in infants and individuals aged ≥ 60 years. RSVpreF received approval for vaccination of pregnant individuals to help protect infants against RSV illness on 21 August 2023 in the USA. RSVpreF is also approved in the USA (31 May 2023) for active immunization of individuals aged ≥ 60 years for the prevention of lower respiratory tract disease (LRTD) caused by RSV. In the EU, RSVpreF has received approval for both indications, and it has been submitted for regulatory approval in Canada (both indications) and in Japan (maternal immunization to protect infants). This article summarizes the milestones in the development of RSVpreF leading to the approval for use in pregnant individuals to prevent LRTD in infants.
Recent advances in the prevention of respiratory syncytial virus in pediatrics

Madeline A. Lipp,Kerry M. Empey

DOI: https://doi.org/10.1097/mop.0000000000001336

2024-03-07

Current Opinion in Pediatrics

Abstract:Respiratory syncytial virus (RSV) is a ubiquitous virus and the leading cause of pediatric hospitalization in the United States. Prevention strategies are key for reducing the burden of RSV. Several new agents aimed at preventing RSV in infants and children were FDA-approved in 2023, and many more are in the development pipeline. This review highlights new developments in RSV prevention in pediatric patients and the important safety considerations for clinical trials.

pediatrics
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults

Zhanwei Du,Shuqi Wang,Ruohan Chen,Songwei Shan,Yuan Bai,Lin Wang,Eric Lau,Peng Wu,Benjamin J. Cowling

DOI: https://doi.org/10.1016/j.jinf.2024.106211

IF: 28.2

2024-06-27

Journal of Infection

Abstract:Highlights • GSK and Pfizer's RSV pre-F vaccines demonstrate promising results in clinical trials of adults with encouraging efficacy. • Approval of RSV pre-F protein vaccines marks a milestone in preventing RSV illnesses in adults. • Continued research is needed for long-term safety and addressing potential risks.

infectious diseases
Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine

Yannic C. Bartsch,Deniz Cizmeci,Dansu Yuan,Nickita Mehta,Jeroen Tolboom,Els De Paepe,Roy van Heesbeen,Jerald Sadoff,Christy A. Comeaux,Esther Heijnen,Benoit Callendret,Galit Alter,Arangassery Rosemary Bastian

DOI: https://doi.org/10.1128/jvi.00771-23

IF: 6.549

2023-11-30

Journal of Virology

Abstract:ABSTRACT An Ad26.RSV.preF/RSV preF protein combination vaccine demonstrated 80.0% vaccine efficacy for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in a phase 2b study. In addition to neutralizing antibodies, Fc-effector functions are associated with protective immunity against RSV. Here, vaccine-induced Fc-effector functions were evaluated for the Ad26.RSV.preF/RSV preF protein vaccine in a subset of participants enrolled in a phase 1/2a study. RSV preF-specific antibody subclasses, isotypes, Fcγ receptor binding, and Fc-effector functions were evaluated on days 1 (pre-vaccination), 15, 29, and 183. Compared with Ad26.RSV.preF or RSV preF protein alone, the combination vaccine induced greater Fc-effector functions, including antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation. Despite RSV pre-exposure, antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation were not observed at baseline but were induced de novo following vaccination. Compared with the individual vaccine components, the combination vaccine induced a more polyfunctional antibody response. IMPORTANCE Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine.

virology
The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation

Paul Trubin,Marwan M Azar,Camille N Kotton,Marwan M. Azar,Camille N. Kotton

DOI: https://doi.org/10.1016/j.ajt.2024.02.003

IF: 9.369

2024-02-01

American Journal of Transplantation

Abstract:In 2023, the Food and Drug Administration approved 2 recombinant subunit respiratory syncytial virus (RSV) vaccines based on prefusion RSV F glycoproteins for the prevention of RSV-associated lower respiratory tract disease. These vaccines were subsequently recommended for individuals ≥60 years of age using shared clinical decision-making by the Center for Disease Control and Prevention's Advisory Committee on Immunization Practices. The development, deployment, and uptake of respiratory virus vaccines are of particular importance for solid organ recipients who are at higher risk of infectious complications and poor clinical outcomes, including from RSV-associated lower respiratory tract disease, compared to patients without immunocompromise. This review aims to summarize what is currently known about the burden of RSV disease in solid organ transplantation, to describe the currently available tools to mitigate the risk, and to highlight considerations regarding the implementation of these vaccines before and after transplantation. We also explore areas of unmet need for organ transplant recipients including questions of RSV vaccine effectiveness and safety, inequities in disease and vaccine access based on race and socioeconomic status, and expansion of coverage to immunocompromised individuals below the age of 60 years.

surgery,transplantation
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine

Ann R Falsey,Edward E Walsh,Daniel A Scott,Alejandra Gurtman,Agnieszka Zareba,Kathrin U Jansen,William C Gruber,Philip R Dormitzer,Kena A Swanson,Qin Jiang,Emily Gomme,David Cooper,Beate Schmoele-Thoma

DOI: https://doi.org/10.1093/infdis/jiab611

2022-06-15

Abstract:Background: Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in older adults and adults with comorbidities. An effective vaccine is needed. An investigational bivalent prefusion F vaccine (RSVpreF) was assessed in healthy adults. Methods: This phase 1/2 study randomized adults 18-85 years old to receive placebo or 60, 120, or 240 µg RSVpreF (with or without aluminum hydroxide) alone or concomitantly with seasonal inactivated influenza vaccine (SIIV). Safety and immunogenicity were assessed. Results: In older adults, reactogenicity events were predominantly mild or moderate among RSVpreF recipients; adverse events through 1 month postvaccination were similar across formulations. Coadministration with SIIV did not appear to affect safety among younger or older adults. All RSVpreF formulations with or without concomitant SIIV elicited robust RSV serum-neutralizing responses in adults aged 50-85 years 1 month postvaccination. Neutralizing titers 1 and 12 months postvaccination were 6.9-14.9 and 2.9-4.5 times, respectively, those before vaccination. SIIV immune responses trended lower when coadministered with RSVpreF. Conclusions: RSVpreF formulations administered alone or with SIIV were well tolerated and highly immunogenic in older adults, supporting the potential for RSVpreF to protect older adults from RSV disease. Clinical trials registration: NCT03529773.
Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease.

DOI: https://doi.org/10.58347/tml.2023.1686a

2023-10-02

Abstract:Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old.

Medicine
Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65

Robert Buynak,Kevin Cannon,David DeAtkine,John Kirby,Lisa Usdan,Amit Bhavsar,Catherine Gérard,Anastasia Kuznetsova,Amulya Jayadev,Hiwot Amare,Sofia Valenciano,Nadia Meyer

DOI: https://doi.org/10.1007/s40121-024-00985-4

2024-07-25

Infectious Diseases and Therapy

Abstract:Respiratory syncytial virus (RSV) and influenza pose major disease burdens in older adults due to an aging immune system and comorbidities; seasonal overlap exists between these infections. In 2023, the RSV prefusion protein F3 older adult (RSVPreF3 OA) vaccine was first approved in the USA as a single dose for prevention of lower respiratory tract disease due to RSV in adults aged ≥ 60 years. The vaccine has since been approved in the European Union and elsewhere. RSVPreF3 OA and FLU-QIV-HD could be coadministered if immunogenicity, safety, and reactogenicity are not affected.

infectious diseases
Research Progress in Respiratory Syncytial Virus Vaccines

Hemeng Yu

DOI: https://doi.org/10.54097/hxt5ey02

2023-12-29

Abstract:In addition to being a substantial source of morbidity and mortality in older persons, respiratory syncytial virus (RSV) is a major contributor to lower respiratory tract infections in newborns and young children. Worldwide, there has been a lot of research done to provide safe and effective vaccinations against this common infection because there isn't an approved RSV vaccine. A succinct summary of current developments in RSV vaccine research is given in this abstract. Many vaccinations have reached the clinical testing stage and shown promising benefits. Live attenuated vaccines, nanoparticle vaccines, and viral vector vaccines are the three primary categories of current vaccination techniques. Additionally, the production of specific RSV antibodies such as MEDI8897 and polyclonal immunoglobulin RI-002 is being evaluated as an important research antibodies for avoiding RSV infection. The continuous dedication to RSV vaccine development gives optimism for the future prevention of RSV-related disorders across all age groups, despite the fact that challenges still exist, particularly ERD (Enhanced respiratory disease).
Human vaccines and immunotherapeutics: News February 2024

Ronald Ellis,Adam Weiss

DOI: https://doi.org/10.1080/21645515.2024.2327910

2024-03-15

Human Vaccines & Immunotherapeutics

Abstract:The US Food and Drug Administration (FDA) has approved the anti-IgE MAb omalizumab (Xolair, Roche) for reduction of allergic reactions and prevention of anaphylaxis following accidental exposure to peanut, milk, egg, wheat, cashew, hazelnut or walnut, in subjects aged 1–55 y.

immunology,biotechnology & applied microbiology
Respiratory syncytial virus prevention is finally here: An overview of safety

Ingrid Laemmle-Ruff,Nigel W Crawford

DOI: https://doi.org/10.31128/AJGP-06-24-7314

Abstract:Background: A number of respiratory syncytial virus (RSV) prevention products have recently been approved in Australia. These products focus on highest risk groups, aiming to prevent RSV disease in young infants and older adults. While not currently included in the National Immunisation Program (NIP), an RSV vaccine (Arexvy, GlaxoSmithKline [GSK]) is available privately for adults ≥60 years, and some Australian jurisdictions have commenced RSV monoclonal antibody (nirsevimab) programs for infants in 2024. Objective: This article summarises safety data regarding RSV prevention products approved in Australia, including vaccines for adults ≥60 years, maternal vaccines and monoclonal antibodies for infants. Discussion: Clinical trial data found these products were largely well tolerated, with most local and systemic reactions being mild-moderate and short-lived. Proportions of serious adverse events were low. While very rare, potential safety signals being further assessed include risk of preterm birth following the maternal vaccine (Abrysvo, Pfizer) and Guillain-Barré syndrome (GBS) following RSV vaccines in older adults (Abrysvo and Arexvy). Close monitoring of these adverse events of special interest via post-licensure surveillance is underway.
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Michael Melgar,Amadea Britton,Lauren E. Roper,H. Keipp Talbot,Sarah S. Long,Camille N. Kotton,Fiona P. Havers

DOI: https://doi.org/10.15585/mmwr.mm7229a4

2023-07-21

Abstract:This report describes respiratory syncytial virus (RSV) vaccine recommendations for adults 60 years and older.

public, environmental & occupational health
RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizations

Marylyn Addo,Oliver Cornely,Michael Denkinger,Georg Ertl,Susanne Herold,Mathias Pletz,Gernot Rohde,Tobias Welte,Wolfram Windisch,Martin Witzenrath

DOI: https://doi.org/10.1007/s15010-023-02141-5

2023-12-08

Infection

Abstract:Respiratory syncytial virus (RSV) inflicts severe illness and courses of infections not only in neonates, infants, and young children, but also causes significant morbidity and mortality in older adults and in people with immunosuppression, hemato-oncologic disease, chronic lung disease, or cardiovascular disease. In June and August 2023, effective vaccines against RSV were approved for the first time by the European Medicines Agency (EMA) for the EU. The respective pivotal studies showed a very high efficacy of the vaccine in preventing severe RSV-associated respiratory infections. At this point, use of the respective vaccines is restricted to persons aged 60 years or older, according to the registration studies. We therefore recommend use of the vaccination in persons aged 60 years or older. In addition, we recommend use of the vaccination in adults of any age with severe pulmonary or cardiovascular pre-existing conditions, as well as in adults with significant immune compromise, after individual consultation with the treating physician. Cost coverage can be applied for individually with the responsible health insurance company.

infectious diseases
Prophylaxis of respiratory syncytial virus infection: current status and prospects for vaccine development

A. S. Korovkin,D. V. Gorenkov,A. R. Volgin

DOI: https://doi.org/10.30895/2221-996x-2024-24-3-255-269

2024-10-03

Abstract:INTRODUCTION . Respiratory syncytial virus (RSV) is one of the most widespread pathogens that typically cause acute upper and lower respiratory tract infections in children and adults. Monoclonal antibody products have long been used for passive immunoprophylaxis in premature infants with bronchopulmonary dysplasia. However, vaccines have recently been licensed for the prophylactic immunisation of older adults with various risk factors for severe RSV infection (primarily, chronic cardiovascular and respiratory diseases and diabetes mellitus). AIM . This study aimed to review the current status of the development of vaccines for active immunisation against RSV infection, including the epidemiological rationale for their development, clinical trial results for licensed vaccines, recommendations for vaccination, and promising pipeline vaccines for RSV prevention. DISCUSSION. Initially hindered by the unique immunopathogenesis of RSV infection and the genetic hypervariability of RSV for a long time, attempts to develop an RSV vaccine succeeded when international researchers managed to identify a conservative neutralising antibody target capable of inducing specific immunity against RSV. This target, the RSV capsid protein stabilised in its prefusion (pre-F) conformation, can mediate viral entry into the cell following a conformational change. Several subunit vaccines based on recombinant pre-F proteins have successfully passed clinical trials and have been approved for the immunisation of older adults. In addition, one of these vaccines has been recommended for use during pregnancy to prevent RSV infection in newborns and infants. Currently, programmes are being implemented to develop novel RSV vaccines based on messenger RNA (mRNA) and non-replicating attenuated influenza vectors. This article examines and summarises the efficacy and safety parameters of two RSV vaccines approved in multiple countries around the world. Both vaccines have satisfactory safety profiles and comparable prophylactic efficacy parameters. CONCLUSIONS. Prelicensure clinical trials of novel RSV vaccines, including those being developed in the Russian Federation, should include prophylactic efficacy assessments in target patient populations. For vaccines approved by leading international regulators, clinical trials required for approval in the Russian Federation will be limited to bridging studies confirming the immunogenicity and safety of the vaccines.
The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review

Jing Shan,Philip N Britton,Catherine L King,Robert Booy

DOI: https://doi.org/10.1111/irv.12850

Abstract:Background: Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infection globally. There are vaccine candidates in development, but a systematic review on immunogenicity and safety of vaccine is lacking. Methods: This systematic review of RSV vaccine clinical trials was undertaken using four databases. Searches were conducted using both controlled vocabulary terms such as "Respiratory Syncytial Virus, Human," "Respiratory Syncytial Virus Infections," "Respiratory Syncytial Virus Vaccines," "Immunization," "Immunization Programs" and "Vaccines" and corresponding text word terms. The included studies were limited to clinical trials published from January 2000 to 31 December 2020. RSV infection case was defined as RSV-associated medically attended acute respiratory illness (MAARI) or RSV infection by serologically confirmed test (Western blot) during the RSV surveillance period. We calculated the relative risk of each vaccine trial with RSV infection case. Results: Of 6306 publications, 38 were included and data were extracted covering four major types of RSV vaccine candidates, these being live-attenuated/chimeric (n = 14), recombinant-vector (n = 6), subunit (n = 12) and nanoparticle vaccines (n = 6). For RSV infection cases, nine trials were involved and none of them showed a vaccine-related increased MAARI during RSV surveillance season. Conclusion: LID ∆M2-2, MEDI M2-2, RSVcps2 and LID/∆M2-2 /1030s (live-attenuated) were considered the most promising vaccine candidates in infant and children. In the elderly, a nanoparticle F vaccine candidate and Ad26.RSV.preF were considered as two potential effective vaccines. A promising maternal vaccine candidate is still lacking.
[Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?]

José M Novoa Pizarro,Birte Christina Lindemann Tappert,Vivian R Luchsinger Farías,Sergio L Vargas Munita

DOI: https://doi.org/10.32641/andespediatr.v94i6.4861

Abstract:Respiratory syncytial virus (RSV) infection is a frequent cause of morbidity and mortality in children. Recently, great advances have been made in the development of new monoclonal antibodies and vaccines thanks to the recognition of the structural conformation of virus proteins. The objective of this study was to review the advances related to the prevention of RSV infection in the first 6 months of life. Advances in structural biology have shown that the RSV fusion protein (F-Protein) in its prefusion state (Pre-F) is an excellent antigen for developing monoclonal antibodies and vaccines to prevent respiratory syncytial virus (RSV) infections. A new single-dose monoclonal antibody, Nirsevimab, has greater neutralizing power than currently available Palivizumab, and prolonged protection for 5 to 6 months. Nirsevimab has demonstrated an efficacy of 76.8% (95% CI, 49.4 to 89.4) in preventing lower respiratory infection 150 days after vaccination, decreasing the risk of ICU admission by 90.1% (95% CI: 16.4-98.8). Clesrovimab is another single-dose monoclonal antibody that has also shown promising results in phase 1b-2a trials. More recently, a bivalent vaccine against RSV A and B (Bivalent Prefusion F) has also been developed by replicating the F-protein stabilized in its Pre-F state as an antigen, using genetic engineering. This antigen, when administered to pregnant women between 24-36 weeks of gestation, induces high levels of antibodies in the mother with high transplacental transfer to the fetus. This vaccine has demonstrated an efficacy of 81.8% (95% CI: 40.6-96.3) at 90 days and 69.4% (95% CI: 44.3-84.1) at 180 days to prevent severe RSV disease (primary endpoint) without safety events detected so far. Nirsevimab and the Pre-F vaccine for pregnant women confer effective protection through passive immunity against RSV that lasts for the first 5 to 6 months of life and have already been approved for use in Europe by the EMA and in Canada and the United States by the FDA.
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date

Charl Verwey,Ziyaad Dangor,Shabir A Madhi

DOI: https://doi.org/10.1007/s40272-023-00606-6

Abstract:Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that include vaccines and long-acting, high-potency monoclonal antibodies. Nirsevimab (Beyfortus™-AstraZeneca/Sanofi), a monoclonal antibody with an extended half-life, has recently been registered in the European Union and granted licensure by the US Food and Drug Administration. Furthermore, a pre-fusion sub-unit protein vaccine has been granted licensure for pregnant women, aimed at protecting their young infants, following established safety and efficacy in clinical trials (Abrysvo™-Pfizer). Also, multiple novel antiviral therapeutic options are in early phase clinical trials. The next few years have the potential to change the landscape of LRTI through improvements in the prevention and management of RSV LRTI. Here, we discuss these new approaches, current research, and clinical trials in novel therapeutics, monoclonal antibodies, and vaccines against RSV infection in infants and children.
Global progress in clinical research on human respiratory syncytial virus vaccines

Ruofan Peng,Chenghao Chen,Qian Chen,Yuwen Zhang,Renjin Huang,Yanjun Zhang,Jianhua Li

DOI: https://doi.org/10.3389/fmicb.2024.1457703

2024-09-02

Abstract:Human respiratory syncytial virus (hRSV) not only affects newborns but also older adults, contributing to a substantial worldwide burden of disease. However, only three approved hRSV vaccines remain commercially available to date. The development of a safe, practical and broad-spectrum vaccine suitable for all age groups remains extremely challenging. Using five different approaches-live-attenuated, recombinant-vector, subunit, particle-based, and mRNA-nearly 30 hRSV vaccine candidates are currently conducting clinical trials worldwide; moreover, > 30 vaccines are under preclinical evaluation. This review presents a comprehensive overview of these hRSV vaccines along with prospects for the development of infectious disease vaccines in the post-COVID-19 pandemic era.

Human vaccines & immunotherapeutics: News May 2023

RSV immunization in adults and children: A practical guide for clinicians

Respiratory Syncytial Virus Prevention: A New Era of Vaccines

Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants

Recent advances in the prevention of respiratory syncytial virus in pediatrics

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine

The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation

Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine

Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease.

Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65

Research Progress in Respiratory Syncytial Virus Vaccines

Human vaccines and immunotherapeutics: News February 2024

Respiratory syncytial virus prevention is finally here: An overview of safety

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizations

Prophylaxis of respiratory syncytial virus infection: current status and prospects for vaccine development

The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review

[Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?]

Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date

Global progress in clinical research on human respiratory syncytial virus vaccines